American College of Clinical Pharmacy
      Search      Cart

Hematology/Oncology PRN and Pharmaceutical Industry PRN Focus Session -- Biosimilars: An Extensive Review for the Clinical Pharmacist

Sunday, October 27, 2019 from 2:15 PM to 3:45 PM EST at 2nd Floor: Murray Hill

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-188-L04-P
Activity Type: A Knowledge-Based Activity

  • Marco  Martino, Pharm.D., MBA, BCPS, BCOPModerator: Marco Martino, Pharm.D., MBA, BCPS, BCOP
    Operations Team Lead (Hematology/Oncology), Northwestern Medicine, Chicago, Illinois
      View Biography

Evaluating Biosimilar Efficacy: Is It All the Same?
2:15 PM


Learning Objectives
1. Outline the process by which biosimilar medications are developed and subsequently FDA-approved.
2. Evaluate the official means to determine if a biosimilar medication is as effective as its brand-name medication.
3. List the hematology/oncology biosimilar medications that are currently FDA-approved and are in the development pipeline.
Show Me the Money: Biosimilar Formulary Decision-Making
3:00 PM

  • Maribel  Pereiras, Pharm.D., BCOPSpeaker: Maribel Pereiras, Pharm.D., BCOP
    Hackensack University Medical Center, Hackensack, New Jersey

Learning Objectives
1. Discuss the process by which healthcare institutions should approve certain biosimilar medications for institution formularies.
2. Describe the pharmacoeconomic impact biosimilar medications can have on an institution formulary.